Tag: CYAD101002
Celyad Oncology announces voluntary suspension of Phase 1b trial CYAD-101-002 – 02/28/2022 at 08:30
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the research and development of T cell-based CAR T cell therapies (…